Harmony Biosciences (HRMY) reported Q4 adjusted earnings Tuesday of $1.08 per diluted share, compared with $0.73 a year earlier.
Analysts surveyed by FactSet expected $0.88.
Net product revenue for the quarter ended Dec. 31 was $201.3 million, compared with $168.4 million a year earlier. Analysts surveyed by FactSet expected $201 million.
The company said it expects net product revenue of $820 million to $860 million for 2025. Analysts surveyed by FactSet expect $844.4 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。